Hematologic Malignancy
Acute Lymphoblastic Leukemia
CI-CAN-00000400ALLExplore in graph →
Hematologic547 active trials12 approved drugs43 evidence items
- NCIt
- C3167
- DOID
- 9952
- MeSH
- D054198
- Other
- 3 more codes
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000400ALLExplore in graph →
Clinical trials
2,037 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (267)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05310591 | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence(CAPTiRALL) | recruiting | Phase 1 / Phase 2 | 26 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05326919 | The Patient Cohort of the National Center for Precision Medicine in Leukemia(eTHEMA) | recruiting | — | 3,000 | Assistance Publique - Hôpitaux de Paris |
| 1 |
| May 29, 2024 |
| clinicaltrials |
| NCT06410833 | Belimumab After Rituximab in Resistant Primary Juvenile SS(BRRPJS) | recruiting | Phase 4 | 15 | Peking Union Medical College HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06346912 | CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL | recruiting | Early Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06381817 | Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients | recruiting | Phase 3 | 146 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 30 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06250959 | RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.(BEAT-ALL-2024) | recruiting | Phase 2 | 124 | Chen SuningOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06242353 | Coagulopathy in Childhood Acute Lymphoblastic Leukaemia(CoagCALL) | not yet recruiting | — | 100 | Karolinska University HospitalOTHER | 0 | Feb 5, 2024 | clinicaltrials |
| NCT06237192 | MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients | recruiting | N/A | 200 | National Research Center for Hematology, RussiaNETWORK | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06220487 | A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL(ABC) | recruiting | Phase 2 | 67 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04105530 | Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL) | active not recruiting | N/A | 36 | St. Jude Children's Research HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT05127148 | RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL | recruiting | — | 100 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06175702 | Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL(LALPh2022) | not yet recruiting | — | 150 | PETHEMA FoundationOTHER | 0 | Dec 19, 2023 | clinicaltrials |
| NCT06136364 | CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study | recruiting | Phase 1 | 9 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06081478 | CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 100 | Beijing Tongren HospitalOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT05515029 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis | active not recruiting | Phase 3 | 56 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT00003861 | Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia | active not recruiting | — | 840 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT05931757 | A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL | not yet recruiting | Phase 2 | 22 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05648019 | CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol | recruiting | Phase 2 | 40 | KK Women's and Children's HospitalOTHER_GOV | 1 | Mar 9, 2023 | clinicaltrials |
| NCT04499573 | Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL | active not recruiting | Phase 1 / Phase 2 | 50 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05682131 | South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol(SCCCG-R-ALL) | recruiting | Phase 4 | 210 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT03852407 | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning(HLA) | recruiting | Phase 2 | 114 | University of LiegeOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04214886 | CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies | active not recruiting | Phase 1 | 24 | Loyola UniversityOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT01744223 | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 36 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03301168 | Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 120 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT04179929 | Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults | recruiting | N/A | 300 | PETHEMA FoundationOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT04746209 | Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT | recruiting | Phase 2 | 25 | Medical College of WisconsinOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT05043571 | CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia | recruiting | Phase 1 | 20 | National University Hospital, SingaporeOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT05009537 | Optical Genome Mapping in Hematological Malignancies(CARTOGEN) | recruiting | — | 200 | University Hospital, BrestOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT03709719 | Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia(GRAALL-QUEST) | active not recruiting | Phase 2 | 95 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT04675918 | Pediatric In-Hospital Cardiac Arrest International Registry (PACHIN)(PACHIN) | recruiting | — | 500 | Jimena del CastilloOTHER | 1 | Jan 19, 2021 | clinicaltrials |
| NCT04227015 | A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy | recruiting | Early Phase 1 | 72 | He HuangOTHER | 1 | Dec 28, 2020 | clinicaltrials |
| NCT04603872 | CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies | recruiting | Early Phase 1 | 120 | Zhejiang UniversityOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT04532203 | A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies | recruiting | Early Phase 1 | 72 | Zhejiang UniversityOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT04532281 | A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies | recruiting | Early Phase 1 | 120 | Zhejiang UniversityOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT04595162 | A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | not yet recruiting | Phase 1 | 12 | Peking University Third HospitalOTHER | 0 | Oct 20, 2020 | clinicaltrials |
| NCT04477967 | Design and Implementation of the Pediatric Liver Transplantation Biobank | recruiting | — | 500 | Children's Hospital of Chongqing Medical UniversityOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT04209244 | Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia | recruiting | N/A | 100 | Rigshospitalet, DenmarkOTHER | 1 | Dec 26, 2019 | clinicaltrials |
Data updated 22 days agoSource updated May 29, 2024source: clinicaltrials